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Abstract
Background. The purpose of this study was to identify
determinants of renal disease progression in adults with
Fabry disease during treatment with agalsidase beta.
Methods. Renal function was evaluated in 151 men and 62
women from the Fabry Registry who received agalsidase
beta at an average dose of 1 mg/kg/2 weeks for at least 2
years. Patients were categorized into quartiles based on
slopes of estimated glomerular filtration rate (eGFR) during
treatment. Multivariate logistic regression analyses were
used to identify factors associated with renal disease pro-
gression.
Results. Men within the first quartile had a mean eGFR
slope of –0.1 mL/min/1.73m2/year, whereas men with the
most rapid renal disease progression (Quartile 4) had a
mean eGFR slope of –6.7 mL/min/1.73m2/year. The risk
factor most strongly associated with renal disease progres-
sion was averaged urinary protein:creatinine ratio (UP/Cr)
1 g/g (odds ratio 112, 95% confidence interval (95% CI)
4–3109, P ¼ 0.0054). Longer time from symptom onset to
treatment was also associated with renal disease progres-
sion (odds ratio 19, 95% CI 2–184, P¼ 0.0098). Women in
Quartile 4 had the highest averaged UP/Cr (mean 1.8 g/g)
and the most rapid renal disease progression: (mean slope
–4.4 mL/min/1.73m2/year).
Conclusions. Adults with Fabry disease are at risk for
progressive loss of eGFR despite enzyme replacement ther-
apy, particularly if proteinuria is 1 g/g. Men with little
urinary protein excretion and those who began receiving
agalsidase beta sooner after the onset of symptoms had
stable renal function. These findings suggest that early in-
tervention may lead to optimal renal outcomes.
Keywords: alpha galactosidase; enzyme replacement therapy; Fabry
disease; genetic renal disease; proteinuria
Introduction
Fabry disease is a rare X-linked systemic disorder, in which
globotriaosylceramide (GL-3) and other glycosphingolipids
accumulate within lysosomes, due to insufficient activity of
a-galactosidase A (a-GalA). Progressive accumulation of
GL-3, particularly in the vascular endothelium, is associated
with chronic kidney disease, cerebrovascular and cardiovas-
cular disease [1]. In the kidneys, GL-3 deposits have been
described in all types of glomerular, tubular, vascular and
interstitial cells [2–5]. Hemizygous males typically experi-
ence the most severe manifestations of Fabry disease [1], but
heterozygous females can also develop major complications
[6–9].
Most men and some women with Fabry disease exhibit
deterioration of renal function [7, 10, 11], and many eventually
develop end-stage renal disease (ESRD) [6, 12]. Although
progression to ESRD is much less common in women, the
median age at which patients reached ESRD (38 years) was
the same in both genders [6, 12]. Studies of untreated patients
with Fabry disease have identified proteinuria as a major risk
factor for renal disease progression [7, 10].
Agalsidase beta, a form of recombinant human a-GalA, is
approved for use as enzyme replacement therapy (ERT) for
Fabry disease (Fabrazyme; Genzyme Corporation,
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Cambridge, MA). In clinical studies, agalsidase beta cleared
microvascular endothelial GL-3 deposits from the kidney,
heart and skin [13, 14]. It also provided long-term stabiliza-
tion of renal function in patients with mild renal involvement
(serum creatinine <2.2 mg/dL) [14] and delayed time to
renal, cardiovascular and cerebrovascular events in patients
with more advanced Fabry disease [15]. Agalsidase beta
treatment did not stabilize renal function in patients with
severe renal
involvement [i.e. proteinuria>1 g/24 h or estimated glomer-
ular filtration rate (eGFR) <60 mL/min/1.73m2] at the time
treatment was started [14, 15].
Randomized clinical trials of ERT for patients with
Fabry disease have been performed on a relatively limited
number of subjects. The Fabry Registry is an observational
database that compiles clinical and laboratory data from
both treated and untreated patients; it was established to
further investigate the long-term effects of ERT and the
natural progression of Fabry disease in a larger population.
The objective of these analyses was to identify determi-
nants of renal disease progression among adult patients
treated with agalsidase beta at a dose of 1 mg/kg/2 weeks.
Materials and methods
As of 3 July 2009, the Fabry Registry included 1429 men and 1458 women
aged18 years. Patients provide informed consent through local Institutional
Review Boards/Ethics Committees and may decline to participate or with-
draw consent at any time. Given the voluntary participation, patients’ ages at
clinical assessments and time intervals between assessments are variable.
To be included in these analyses, patients must have received agalsidase
beta at an average dose at or near the recommended licensed dose of 1 mg/kg/
2 weeks (0.9 to1.1 mg/kg/2 weeks). Patients must have had at least three
serum creatinine values reported over a span of at least 2 years after their first
agalsidase beta infusion, with at least one of the three eGFR assessments
reported within 3 months before or after their first infusion and at least one
urinary protein:creatinine ratio (UP/Cr) value reported within 3 months before
or after their first infusion. Both spot and 24-h UP/Cr values were used to
calculate UP/Cr values and the average of all UP/Cr values reported during
the follow-up period was calculated for patients with multiple values.
Data were collected prior to any chronic dialysis or kidney transplan-
tation. Cardiovascular clinical events were defined as myocardial infarc-
tion, congestive heart failure, arrhythmia, angina pectoris or a significant
cardiac procedure (e.g. pacemaker or other implantable cardiac device
placement, bypass, stent placement, valve replacement, transplantation).
Cerebrovascular events were defined as stroke.
eGFR was calculated from serum creatinine values, using the Chronic
Kidney Disease Epidemiology Collaboration equation [16]. Regression
slopes representing an individual’s change in eGFR following initiation
of treatment were calculated based on eGFR values reported after the first
infusion. Patients were grouped into quartiles, based on eGFR slope.
Logistic regression analyses were used to identify factors associated
with men in Quartile 1 (Q1) compared to men in Quartile 4 (Q4). Propor-
tional odds regression analyses were used to identify predictors in men
across quartiles. Baseline eGFR, averaged UP/Cr, the occurrence a cardi-
ovascular or cerebrovascular clinical event prior to the initiation of treat-
ment, age at first infusion, time from diagnosis to first infusion, time from
symptom onset to first infusion and averaged systolic and diastolic blood
pressure were used as predictor variables. Results from logistic regression
and proportional odds regression are expressed as odds ratios, with
corresponding 95% confidence intervals (95% CI) and P-values. Because
there were fewer women in the cohort, a simplified logistic regression
model was created by including fewer covariates and by combining
data from women in Q1–Q3 and comparing these against data from
women in Q4.
Statistical analyses were performed using SAS statistical software ver-
sion 9.1 (SAS Institute Inc., Cary, NC). An alpha-level of 0.05 was used as
the cut-point to determine statistical significance.
Results
One hundred fifty-one men and 62 women met the inclu-
sion criteria, including a baseline UP/Cr value and three or
more eGFR values (see Materials and methods); 95% of the
men and 92% of the women had two or more UP/Cr values
reported during the treatment period. The median age at
initiation of agalsidase beta treatment was 38 years for
men and 43 years for women. Men were followed for 5
 1.9 years (mean  SD) and women for 4  1.6 years.
The 38 men in Q1 (those with the most stable renal func-
tion) had a mean eGFR slope of 0.1 mL/min/1.73m2/year,
whereas the 37 men in Q4 (those with the fastest renal dis-
ease progression) had a mean eGFR slope of 6.7 mL/min/
1.73m2/year. Clinical characteristics for these patients are
shown in Table 1. Men in Q1 had lower mean averaged
UP/Cr levels than those in Q4: 0.7 versus 1.7 g/g. Men in
Q1 also had higher mean baseline eGFR levels than men in
Q4: 99 versus 72 mL/min/1.73m2 (i.e. eGFR at the time
treatment was initiated). Men in Q1 initiated agalsidase beta
treatment sooner after the onset of Fabry symptoms than men
in Q4: median 20 versus 35 years. Mean averaged blood
pressure levels were similar across quartiles.
Clinical characteristics of women are shown in Table 2.
Like men, women in Q4 tended to have higher UP/Cr levels
than women in Q1. There were no apparent differences
across quartiles in baseline eGFR levels, time from symp-
tom onset to first infusion or age at first infusion in women.
Averaged blood pressure levels in women were within or
slightly above the normal range across quartiles.
In both genders, fewer patients in Q1 had experienced a
stroke or cardiovascular event (as defined in Materials and
methods) prior to the initiation of agalsidase beta treatment
compared to patients in Q4 (Figure 1). Patients in each
quartile were categorized by mutation type and by specific
genotype (Table 3). Men with nonsense mutations (n¼ 16)
were more likely to be in Q3–Q4 (n ¼ 12, 75%) than in
Q1–Q2 (n ¼ 4, 25%). Conversely, men with missense
mutations (n ¼ 71) were more likely to be in Q1–Q2
(n ¼ 44, 62%) than Q3–Q4 (n ¼ 27, 38%). The five most
prevalent missense genotypes are shown in Table 3. Most
patients had unique genotypes and there was no clear
association between any specific genotype and renal
function.
Results of the logistic regression model comparing men in
Q1 to men in Q4 are shown in Table 4. Among the 75 men in
Q1 and Q4, those who had averaged UP/Cr levels 1.0 g/g
had a 112-fold increase in the risk of having more rapid renal
disease progression (i.e. being in Q4) than did men who had
averaged UP/Cr levels <0.3 g/g (odds ratio 112, 95% CI
4.0–3108.9, P ¼ 0.0054). In addition to averaged UP/Cr,
the time from symptom onset to first agalsidase beta infusion
was also strongly associated with renal disease progression.
Men in whom the time from symptom onset to first infusion
was greater than the median (24 years) had a 19-fold increase
in the risk of being in Q4 than men who initiated treatment
sooner (odds ratio 19, 95% CI 2.0–183.9, P ¼ 0.0098).
When UP/Cr was removed from the regression model, lower
baseline eGFR also emerged as a significant risk factor for
renal disease progression in men; men with eGFR <60 mL/
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min/1.73m2 at baseline had a 12-fold increase in the risk of
being in Q4 than men who had higher eGFR levels (odds
ratio 12, 95% CI 1.2–114.0, P ¼ 0.0316).
A proportional odds regression model was used to eval-
uate factors associated with renal disease progression in
men across quartiles, as shown in Table 5. As in the logistic
regression model of Q1 versus Q4, higher averaged UP/Cr
(1 versus <0.3 g/g) was the variable most strongly associ-
ated with renal disease progression in men across quartiles.
Among the 151 men in this cohort, those with averaged UP/Cr
1 g/g had a 4.5-fold higher risk of renal disease progression
(i.e. more negative eGFR slope) compared to those with UP/Cr
<0.3 g/g (odds ratio 4.5, 95% CI 1.9–10.7, P ¼ 0.0006). The
time from symptom onset to initiation of treatment was also a
significant factor; men who initiated treatment>24 years after
symptom onset had a 2.9-fold higher risk of renal disease
progression compared to those who initiated treatment sooner
(odds ratio 2.9, 95% CI 1.3–6.7, P ¼ 0.0113). When UP/Cr
was removed from the proportional odds regression model,
lower baseline eGFR, the occurrence of a stroke or
cardiovascular event prior to initiation of treatment and time
from symptom onset to initiation of treatment were significant
factors associated with renal disease progression in men
(Table 5).
It was more difficult to develop a suitable logistic regression
model for predictors of eGFR slope among the smaller num-
ber of women in this cohort (n ¼ 15 or 16 in each quartile).
For this reason, women in Q1–Q3 were combined, as their
mean averaged UP/Cr levels and baseline eGFR values were
similar (see Materials and methods and Table 2). When
covariates were limited to averaged UP/Cr, age at first infusion
and time from symptom onset to initiation of treatment, aver-
aged UP/Cr was found to be associated with renal disease
progression in women (Table 6). Among all 62 women, those
who had averaged UP/Cr levels 1.0 g/g had a 12-fold in-
creased risk of having more rapid renal disease progression
(i.e. being in Q4) than did women who had averaged UP/Cr
levels <0.3 g/g (odds ratio 11.7, 95% CI 1.1–119.7, P ¼
0.0388). When UP/Cr was removed from the regression
model, age at first infusion also appeared as a significant risk
factor. Women who received their first infusion at age 40
years had a 7-fold increase in the risk of being in Q4 compared
to women who received their first infusion at a younger age
(odds ratio 7.4, 95% CI 1.12–48.3, P ¼ 0.0375). Time from
symptom onset to first infusion was not a significant predictor
of renal disease progression in women; however, only a subset
of women had reported the age at which they first experienced
symptoms of Fabry disease (n ¼ 42).
Table 1. Clinical characteristics of men during agalsidase beta treatmenta
eGFR slope Quartile 1
(1.2 to 15.3)
eGFR slope Quartile 2
(2.8 to 1.3)
eGFR slope Quartile 3
(4.8 to 2.9)
eGFR slope Quartile 4
(15.5 to 4.9)
eGFR slope (mL/min/1.73m2/year), n 38 38 38 37
Mean (SD) 0.1 (1.20) 2.1 (0.52) 3.8 (0.61) 6.7 (2.26)
Median (25th, 75th) 0.5 (0.9, 0.6) 2.1 (2.6, 1.5) 3.6 (4.3, 3.3) 6.2 (6.9, 5.5)
Averaged UP/Cr (g/g), n 38 38 38 37
Mean (SD) 0.7 (0.80) 0.7 (0.78) 0.8 (0.86) 1.7 (1.21)
Median (25th, 75th) 0.3 (0.1, 0.9) 0.4 (0.2, 1.1) 0.6 (0.3, 1.1) 1.5 (1.1, 2.0)
Pre-treatment (baseline) eGFR (mL/min/
1.73m2), n
37 37 38 36
Mean (SD) 99 (22.6) 77 (32.9) 88 (38.7) 72 (34.3)
Median (25th, 75th) 104 (89, 115) 73 (46, 108) 88 (51, 123) 61 (47, 95)
Averaged SBP (mmHg), n 38 38 38 37
Mean (SD) 119 (11.8) 122 (10.0) 121 (9.5) 125 (10.8)
Median (25th, 75th) 120 (110, 126) 122 (114, 128) 122 (116, 127) 125 (115, 132)
Averaged DBP (mmHg), n 38 38 38 37
Mean (SD) 71 (8.7) 73 (7.7) 73 (8.1) 74 (6.6)
Median (25th, 75th) 70 (64, 77) 72 (68, 78) 74 (67, 79) 73 (71, 79)
Reported ACEi/ARB use, n (%) 13 (34.2) 19 (50.0) 19 (50.0) 19 (51.4)
Stroke or cardiovascular eventb prior to first
infusion, n (%)
3 (7.9) 13 (34.2) 13 (34.2) 17 (45.9)
Time from symptom onset to first agalsidase
beta infusion (years), n
35 31 31 32
Mean (SD) 20.2 (10.92) 22.4 (13.92) 20.4 (12.63) 31.9 (12.34)
Median (25th, 75th) 19.9 (12.9, 28.2) 20.3 (13.1, 31.6) 18.9 (10.9, 30.1) 34.6 (26.0, 41.7)
Time from diagnosis to first agalsidase beta
infusion (years), n
38 38 38 37
Mean (SD) 6.7 (7.50) 7.5 (10.45) 9.0 (11.05) 10.7 (11.86)
Median (25th, 75th) 3.2 (0.9, 13.3) 2.1 (0.6, 7.5) 2.4 (0.7, 18.5) 4.0 (0.6, 22.2)
Age at first infusion (years), n 38 38 38 37
Mean (SD) 35.3 (11.04) 40.7 (11.12) 37.0 (10.91) 42.0 (9.22)
Median (25th, 75th) 34.7 (27.5, 41.9) 41.9 (33.2, 51.1) 37.1 (27.9, 46.1) 42.7 (35.7, 48.0)
aSBP, systolic blood pressure; DBP, diastolic blood pressure; 25th, 25th percentile value; 75th, 75th percentile value. All data are from adult Fabry
Registry patients (18 years) with three or more eGFR assessments (calculated by Chronic Kidney Disease Epidemiology Collaboration equation) over a
period of 2 years (at least one eGFR assessment within 3 months of initiation of agalsidase beta treatment) and prior to any chronic dialysis or renal
transplant events. ‘Averaged’ UP/Cr and blood pressure data reflect the average of all values reported within 3 months of the date of the first agalsidase
beta infusion to the most recent assessment during treatment. Baseline eGFR is based on the assessment date closest to a patient’s first infusion of
agalsidase beta (within 3 months of the first infusion).
bCardiovascular events were defined as described in ‘Materials and methods’.
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Discussion
The purpose of these analyses was to evaluate renal func-
tion during agalsidase beta treatment and to identify deter-
minants of renal disease progression during treatment. Our
findings demonstrate that baseline clinical status plays a
critical role in renal outcomes during agalsidase beta treat-
ment. Higher urinary protein levels, poorer initial renal
function and delayed initiation of agalsidase beta treatment
after the onset of Fabry symptoms were independent pre-
dictors strongly associated with renal disease progression
in men. In proportional odds regression analyses across
quartiles, the occurrence of a stroke or cardiovascular event
prior to the initiation of agalsidase beta treatment was also
associated with more rapid renal disease progression in
men.
Men generally have more severe manifestations of Fabry
disease than women [1, 9] and a higher proportion of men
are treated with ERT [9]. The smaller number of women
who received treatment and met the inclusion criteria
limited the analysis of women in this cohort. Renal function
among the women in Q1–Q3 appeared to be similar to or
more stable than the normal expected rate of renal decline
of –1 mL/min/1.73m2/year in the general population [17,
18]. However, like men, women who had the most rapid
renal disease progression also had the highest averaged
UP/Cr levels.
These findings are consistent with results from the open-
label extension of a placebo-controlled double-blind Phase
3 clinical study [14] and a placebo-controlled double-blind
Phase 4 clinical study [15] of agalsidase beta at a dose of
1 mg/kg/2 weeks. The clinical studies demonstrated that
men with urinary protein levels 1 g/24 h and men with
lower baseline eGFR had a poorer response to agalsidase
beta than those with lower urinary protein levels and better
baseline eGFR [14, 15]. There were too few female patients
in either study to make meaningful comparisons to the
present analyses. Our findings are consistent with a recent
analysis of data from untreated Fabry Registry patients,
which identified proteinuria as the predominant risk factor
for renal disease progression, especially in men [10]. Sim-
ilar findings were reported in a retrospective chart review of
clinical data from untreated Fabry patients [7].
Table 2. Clinical characteristics of women during agalsidase beta treatmenta
eGFR slope
Quartile 1 (11.1
to 17.5)
eGFR slope
Quartile 2 (0.4
to 11.0)
eGFR slope
Quartile 3 (2.3
to 0.4)
eGFR slope
Quartile 4 (7.6
to 2.4)
eGFR slope (mL/min/1.73m2/year), n 15 16 16 15
Mean (SD) 2.7 (1.65) 0.1 (0.41) 1.3 (0.66) 4.4 (1.58)
Median (25th, 75th) 2.6 (1.3, 3.4) 0.1 (0.2, 0.4) 1.4 (1.7, 0.6) 4.2 (5.5, 3.0)
Averaged UP/Cr (g/g), n 15 16 16 15
Mean (SD) 0.8 (1.47) 0.9 (1.03) 0.6 (0.86) 1.8 (1.65)
Median (25th, 75th) 0.2 (0.1, 0.6) 0.5 (0.2, 1.1) 0.3 (0.1, 0.7) 1.3 (0.5, 2.9)
Pre-treatment (baseline) eGFR (mL/min/1.73m2), n 14 14 16 14
Mean (SD) 88 (16.0) 90 (23.9) 95 (27.6) 78 (35.6)
Median (25th, 75th) 87 (75, 100) 93 (72, 111) 98 (76, 118) 85 (36, 105)
Averaged SBP (mmHg), n 14 16 16 15
Mean (SD) 124 (15.5) 122 (10.7) 117 (10.8) 129 (16.0)
Median (25th, 75th) 126 (111, 135) 121 (114, 129) 117 (113, 121) 127 (120, 140)
Averaged DBP (mmHg), n 14 16 16 15
Mean (SD) 74 (9.7) 75 (6.3) 73 (7.0) 76 (11.1)
Median (25th, 75th) 70 (69, 80) 76 (71, 81) 73 (67, 80) 77 (65, 81)
Reported ACEi/ARB use, n (%) 8 (53.3) 10 (62.5) 9 (56.3) 11 (73.3)
Stroke or cardiovascular eventb prior
to first infusion, n (%)
3 (20.0) 1 (6.3) 5 (31.3) 6 (40.0)
Time from symptom onset to first agalsidase
beta infusion (years), n
10 11 11 10
Mean (SD) 19.5 (14.00) 24.7 (14.38) 21.0 (14.57) 18.2 (16.15)
Median (25th, 75th) 24.2 (1.9, 31.3) 31.4 (7.9, 34.5) 13.4 (10.1, 34.9) 10.8 (6.8, 33.4)
Time from diagnosis to first agalsidase
beta infusion (years), n
15 16 16 15
Mean (SD) 5.7 (6.71) 4.3 (8.29) 6.3 (8.58) 8.0 (10.03)
Median (25th, 75th) 3.2 (0.4, 6.6) 0.8 (0.5, 2.6) 2.4 (0.4, 11.3) 3.8 (0.5, 13.0)
Age at first agalsidase beta infusion (years), n 15 16 16 15
Mean (SD) 43.2 (11.30) 41.0 (11.83) 40.5 (15.12) 47.4 (13.09)
Median (25th, 75th) 45.8 (33.5, 51.6) 35.5 (33.5, 52.5) 43.8 (23.6, 51.6) 43.6 (41.4, 57.6)
aSBP, systolic blood pressure; DBP, diastolic blood pressure; 25th, 25th percentile value; 75th, 75th percentile value. All data are from adult Fabry
Registry patients (18 years) with three or more eGFR assessments (calculated by Chronic Kidney Disease Epidemiology Collaboration equation) over a
period of 2 years (at least one eGFR assessment within 3 months of initiation of agalsidase beta treatment) and prior to any chronic dialysis or renal
transplant events. ‘Averaged’ UP/Cr and blood pressure data reflect the average of all values reported within 3 months of the date of the first agalsidase
beta infusion to the most recent assessment during treatment. Baseline eGFR is based on the assessment date closest to a patient’s first infusion of
agalsidase beta (within 3 months of the first infusion).
bCardiovascular events were defined as described in ‘Materials and methods’.
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Table 3. Genotype and eGFR slope quartiles
Males Females
eGFR slope
Quartile 1
(1.2 to 15.3),
N ¼ 38
eGFR slope
Quartile 2
(2.8 to 1.3),
N ¼ 38
eGFR slope
Quartile 3
(4.8 to 2.9),
N ¼ 38
eGFR slope
Quartile 4
(15.5 to 4.9),
N ¼ 37
eGFR slope
Quartile 1
(11.1 to 17.5),
N ¼ 15
eGFR slope
Quartile 2
(0.4 to 11.0),
N ¼ 16
eGFR slope
Quartile 3
(2.3 to 0.4),
N ¼ 16
eGFR slope
Quartile 4
(7.6 to 2.4),
N ¼ 15
Mutation type, n (%)a
Nonsense 3 (18.8) 1 (3.6) 5 (31.3) 7 (43.8) 3 (23.1) 3 (23.1) 2 (15.4) 5 (38.5)
Missense 23 (32.4) 21 (29.6) 15 (21.1) 12 (16.9) 5 (17.2) 10 (34.5) 9 (31.0) 5 (17.2)
Splice site 0 2 (40.0) 2 (40.0) 1 (20.0) 0 0 1 (50.0) 1 (50.0)
Frameshift 3 (25.0) 2 (16.7) 4 (33.3) 3 (25.0) 3 (50.0) 3 (50.0) 0 0
Intronic 0 1 (100.0) 0 0 0 0 0 0
Initiator codon 0 1 (100.0) 0 0 0 0 0 0
Small deletion
(no frameshift)
2 (66.7) 1 (33.3) 0 0 0 0 0 0
Small insertion
(no frameshift)
0 0 0 0 0 0 1 (100.0) 0
Other 0 0 0 1 (100.0) 0 0 1 (100.0) 0
Not available 7 (17.1) 9 (22.0) 12 (29.3) 13 (31.7) 4 (40.0) 0 2 (20.0) 4 (40.0)
Five most prevalent missense
genotypes, n (%)b
N215S 2 (2.8) 1 (1.4) 2 (2.8) 0 0 0 0 1 (3.4)
L415P 4 (5.6) 0 0 0 0 0 0 0
R301Q 2 (2.8) 2 (2.8) 0 0 0 0 0 0
P259R 1 (1.4) 0 0 1 (1.4) 1 (3.4) 1 (3.4) 0 0
C52G 1 (1.4) 0 0 0 0 2 (6.9) 0 0
aFor mutation type, percentages were calculated based on the total number of patients with each type of mutation, by gender.
bThese five missense mutations (N215S, L415P, R301Q, P259R and C52G) were the only genotypes reported by more than two patients in this cohort. Percentages for these five genotypes were calculated based on
the total number of patients who reported missense mutations, by gender (n ¼ 71 men and n ¼ 29 women).
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These findings underscore the possible importance of
controlling proteinuria in patients with Fabry disease.
ERT alone does not appear to decrease proteinuria [14,
15, 19–21] and it has been recommended that patients re-
ceiving ERT also receive angiotensin converting enzyme
inhibitors or angiotensin receptor blockers (ACEi/ARBs) to
reduce proteinuria [22–25]. Only 46% of men in this cohort
and 61% of women reported receiving ACEi/ARBs at any
time during agalsidase beta treatment. This may underesti-
mate the actual percentage of patients treated with ACEi/
Table 4. Logistic regression modeling of renal disease progression in men: eGFR slope Q1 versus eGFR slope Q4a
Odds ratio (95% CI)
UP/CR included in model No UP/Cr in model
Higher averaged UP/Cr (0.3 to <1.0 versus 1.0 g/g) 2.29 (0.35, 14.99) –
Higher averaged UP/Cr (<0.3 versus 1.0 g/g) 111.85 (4.02, 3108.89)* –
Lower baseline eGFR (<60 mL/min/1.73m2) 9.31 (0.74, 116.62) 11.91 (1.24, 114.02)*
Had a stroke or cardiovascular eventb prior to first infusion 1.41 (0.20, 10.08) 4.57 (0.83, 25.22)
Older age at first infusion (<30 versus 50 years) 0.51 (0.01, 20.83) 0.23 (0.01, 0.521)
Older age at first infusion (30 to <40 versus 50 years) 2.53 (0.13, 49.50) 1.31 (0.12, 14.85)
Older age at first infusion (40 to <50 versus 50 years) 1.13 (0.05, 25.84) 0.64 (0.05, 8.23)
Longer time from Fabry diagnosis to first infusion (>median, 2.6 years) 0.62 (0.11, 3.54) 0.85 (0.22, 3.36)
Longer time from Fabry symptom onset to first infusion (>median, 24 years) 19.39 (2.05, 183.88)* 10.22 (1.57, 66.37)*
Higher averaged systolic blood pressure (>120 mmHg) 0.36 (0.05, 2.75) 1.48 (0.36, 6.01)
Higher averaged diastolic blood pressure (>80 mmHg) 0.71 (0.05, 10.62) 1.12 (0.10, 12.40)
aAnalyses were based on n ¼ 38 males in eGFR slope Q1 and n¼ 37 males in eGFR slope Q4 for all parameters except ‘time from first symptom to first
infusion’. Because several patients did not have a date of symptom onset available, this parameter included n ¼ 35 males in eGFR slope Q1 and n¼32
males in eGFR slope Q4.
bCardiovascular events were defined as described in ‘Materials and Methods.
*P < 0.05 by the Wald test.
Table 5. Proportional odds regression modeling of renal disease progression in men across eGFR slope quartilesa
Odds ratio (95% CI)
UP/Cr included in model No UP/Cr in model
Higher averaged UP/Cr (0.3 to <1.0 versus 1.0 g/g) 1.59 (0.69, 3.68) –
Higher averaged UP/Cr (<0.3 versus 1.0 g/g) 4.52 (1.90, 10.75)* –
Lower baseline eGFR (<60 mL/min/1.73m2) 2.42 (0.97, 6.03) 2.86 (1.18, 6.94)*
Had a stroke or cardiovascular eventb during natural history period 2.19 (0.99, 4.84) 2.28 (1.05, 4.98)*
Older age at first infusion (<30 versus 50 years) 0.41 (0.11, 1.57) 0.55 (0.15, 1.99)
Older age at first infusion (30 to <40 versus 50 years) 0.83 (0.27, 2.51) 0.82 (0.28, 2.44)
Older age at first infusion (40 to <50 versus 50 years) 1.27 (0.43, 3.73) 1.22 (0.42, 3.51)
Longer time from Fabry diagnosis to first infusion (>median, 2.6 years) 0.85 (0.42, 1.71) 0.87 (0.44, 1.75)
Longer time from Fabry symptom onset to first infusion (>median, 24 years) 2.92 (1.27, 6.68)* 3.27 (1.47, 7.26)*
Higher averaged systolic blood pressure (>120 mmHg) 1.07 (0.54, 2.14) 1.03 (0.52, 2.04)
Higher averaged diastolic blood pressure (>80 mmHg) 1.38 (0.49, 3.85) 1.63 (0.61, 4.37)
aAnalyses were based on N¼ 151 males for all parameters except ‘time from first symptom to first infusion’. Because some patients did not have a date of
symptom onset available, this parameter included n ¼ 129 males across eGFR slope quartiles.
bCardiovascular events were defined as described in ‘Materials and methods’.
*P < 0.05 by the Wald test.
Table 6. Logistic regression modeling of renal disease progression in women: eGFR slope Q1, Q2 and Q3 versus eGFR slope Q4a
Odds ratio (95% CI)
UP/CR included in model No UP/Cr in model
Higher averaged UP/Cr (0.3 to <1.0 versus 1.0 g/g) 2.09 (0.25, 17.46) –
Higher averaged UP/Cr (<0.3 versus 1.0 g/g) 11.66 (1.14, 119.73)* –
Older age at first infusion (40 years) 4.85 (0.66, 35.70) 7.36 (1.12, 48.29)*
Longer time from Fabry symptom onset to first infusion (>median, 24 years) 0.31 (0.047, 2.041) 0.29 (0.055, 1.55)
aAnalyses were based on n ¼ 47 females in eGFR slope Q1–Q3 (combined) and n ¼ 15 females in eGFR slope Q4 for all parameters except ‘time from
first symptom to first infusion’. Because some patients did not have a date of symptom onset available, this parameter included n ¼ 32 females in eGFR
slope Q1–Q3 (combined) and n ¼ 10 females in Q4.
*P < 0.05 by the Wald test.
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ARBs, due to the voluntary nature of reporting data to the
Fabry Registry. However, there may also be reluctance
among physicians to prescribe ACEi/ARBs for Fabry pa-
tients who have normal or low baseline systemic blood
pressure. A growing body of evidence suggests that the
benefits of reducing proteinuria outweigh the risks of re-
ducing blood pressure in patients receiving ERT [14, 15,
21, 26]. An open-label prospective evaluation specifically
examined the effects of ACEi/ARB therapy in 11 patients
with Fabry disease who received agalsidase beta at the pre-
scribed dose of 1 mg/kg/2 weeks in conjunction with ACEi/
ARB therapy [26]. Sustained reductions in proteinuria were
associated with stable renal function over a 30-month follow-
up period with no serious complications from hypotension;
in fact, the measured blood pressure levels returned to the
baseline levels after kidney function was stabilized during
the course of anti-proteinuric therapy [26].
Although agalsidase beta treatment may have slowed
renal disease progression in the men in Q3 and Q4, renal
function continued to decline in these patients over the
follow-up period. In contrast, the men in Q1, who had little
urinary protein excretion, higher baseline eGFR levels, and
who began receiving agalsidase beta sooner after the onset
of Fabry symptoms had stable renal function over the
course of their treatment (mean slope –0.1 mL/min/
1.73m2). These findings are also consistent with those from
the open-label Phase 3 extension study of agalsidase beta at
a dose of 1 mg/kg/2 weeks [14]. In that study, patients who
had baseline UP/Cr levels <1 g/24 h had stable renal func-
tion over a 54-month treatment period (eGFR slope –1.0
mL/min/1.73m2/year), whereas patients with baseline
UP/Cr levels 1 g/24 h exhibited rapid renal disease pro-
gression (eGFR slope –7.4 mL/min/1.73m2/year).
Agalsidase alfa, another form of recombinant human
a-GalA (Shire Human Genetic Therapies Inc., Cambridge,
MA), has a recommended licensed dose of 0.2 mg/kg/2
weeks. In a secondary, pooled analysis of data from clinical
studies, West et al. [21] reported that patients treated with
agalsidase alfa who had baseline UP/Cr levels>1 g/24 h also
had more rapid renal disease progression than patients with
lower baseline UP/Cr levels (–6.4 versus –2.11 mL/min/
1.73m2/year). Mehta et al. [27] reported an eGFR slope of
–3 mL/min/1.73m2/year in men in the Fabry Outcome Sur-
vey observational database who were treated with agalsidase
alfa at a dose of 0.2 mg/kg/2 weeks and who remained on
this therapy for 5 years. However, urinary protein levels were
not included as part of those analyses [27], making it difficult
to interpret the eGFR slope data in this context [28].
Various limitations are associated with analysing observa-
tional data from a disease registry, particularly for rare dis-
eases with small numbers of patients. Many patients who
were treated with agalsidase beta were not included in these
analyses because they did not have the required number of
eGFR and UP/Cr assessments reported. Patients who re-
ceived frequent renal assessments may have higher UP/Cr
levels at baseline, which could lead to an over-representation
of patients with more severe renal disease. Interpretation of
these findings is also limited by the lack of an appropriate
parallel control group, such as those included in randomized
clinical trials with agalsidase beta [13, 15]. Many of the
patients were enrolled in the Fabry Registry at the time they
began receiving ERT, so it was not possible to compare the
eGFR slopes before and after treatment for individual
patients. A recent analysis of Fabry Registry data reported
that during the natural history period, renal function declined
at a rate of –5.6 mL/min/1.73m2/year in men with mean
averaged UP/Cr>1.5 g/g [10]. However, the current findings
might not be directly comparable with those of Wanner et al.
[10] because patients in the natural history cohort were
younger and had less severe renal involvement (i.e. higher
baseline eGFR) than patients in the current cohort. If in fact,
the eGFR slope was similar in ERT treated and untreated
men with heavy proteinuria, this would speak strongly for
studies to examine additional treatment strategies such as
proteinuria lowering, earlier institution of therapy and ERT
doses >0.2 mg/kg/2 weeks [29].
The timing of initiation of ERT could be confounded if
there were a significant number of patients in the Fabry
Registry cohort with ‘late-onset mutations’, such as
N215S [30, 31]. Because the majority of mutations in
Fabry disease are unique to individual family groups, there
were very few patients within any single genotype. Six
patients in this cohort had the N215S mutation (Table 3).
Although these patients may have had later onset disease
manifestations than others, there was no clear trend be-
tween this genotype and renal disease progression. The
limited number of such cases did not affect the results or
conclusions of these analyses. As expected, men with non-
sense mutations generally had poorer renal function than
men with missense mutations in the GLA gene.
These findings provide further evidence that it is critical
to closely monitor urinary protein levels in patients treated
with ERT and support the hypothesis that proteinuria
should be aggressively managed with ACEi/ARBs to a
pre-specified treatment target [11, 25]. ACEi/ARBs in con-
junction with ERT can reduce proteinuria and stabilize
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Fig. 1. Patients with rapid renal disease progression experienced clinical
events prior to the initiation of agalsidase beta treatment. Patients were
grouped into quartiles (Q), based on eGFR slope. Data are expressed as
the percentage of patients within each eGFR slope quartile who had a
stroke or cardiovascular event (as defined in Materials and Methods
section) prior to the initiation of agalsidase beta treatment. The numbers
above each bar indicate number of patients who had clinical events prior
to the initiation of treatment/total number of patients in each quartile.
Data for males are shown in light grey bars and data for females are
shown in dark grey bars.
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renal function in Fabry patients [26]. This is a key issue, as
ERT alone does not decrease overt proteinuria in Fabry
disease [14, 15, 19]. These findings also highlight the im-
portance of early initiation of ERT, before the first clinical
signs of kidney dysfunction appear, because substantial
organ damage can occur before proteinuria or loss of eGFR
can be detected [32]. A shorter time from the onset of Fabry
symptoms until the initiation of treatment was associated
with the best renal outcomes among men. Finally, the fact
that agalsidase beta was not an approved therapy at the time
that most of these patients began experiencing disease
symptoms must be considered when interpreting these find-
ings. Men did not begin receiving agalsidase beta until an
overall median of 24 years after their Fabry symptoms
began (median 35 years among men in Q4). With increased
awareness of Fabry disease and the availability of ERT,
younger patients who begin agalsidase beta treatment
sooner after the onset of Fabry symptoms would be ex-
pected to have the most favourable renal outcomes.
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